Table 1.
Characteristics of the studies included in the quantitative meta-analysis
| Study | Setting | Location | Treatment regimen | Number of patients in the considered population for safety (bevacizumab/ranibizumab) | Analysis Population for primary outcome | Number of patients in the considered population for primary outcome (bevacizumab/ranibizumab) | Number of randomised patients (bevacizumab/ranibizumab) |
|---|---|---|---|---|---|---|---|
| GEFAL, 20134 | Multi-centre | France | As-needed | 255/246 | Per protocol | 191/183 | 246/239 |
| MANTA, 20135 | Multi-centre | Austria | As-needed | 321 overall | ITT | 154/163* | 154/163 |
| IVAN, 20123 | Multi-centre | England | As-needed and Monthly | 305/323 | ITT | 251/269 | 296/314 |
| CATT (monthly), 20112 | Multi-centre | USA | Monthly | 1,208 overall | ITT | 265/284 | 286/301 |
| CATT (as needed), 20112 | Multi-centre | USA | As-needed | ITT | 271/285 | 300/298 | |
| Subramanian et al., 201012 | Single centre | USA | As-needed | 20/8 | Available patients | 15/7 | 20/8 |
ITT intention to treat
aSpecific data were not available to be included in the meta-analysis